Nurix Therapeutics, Inc.
NASDAQ:NRIX
9.11 (USD) • At close September 2, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 44.056 | 18.453 | 13.284 | 12.588 | 12.092 | 16.585 | 15.159 | 18.467 | 30.676 | 12.685 | 6.783 | 10.791 | 11.432 | 9.621 | 7.396 | 10.252 | 7.091 | 5.011 | 6.689 | 4.085 | 4.182 | 2.864 | 1.862 | 10.58 | 9.439 | 9.234 |
| Cost of Revenue
| 0 | 0 | 4.303 | 4.146 | 4.091 | 3.888 | 3.757 | 3.384 | 3.333 | 3.18 | 3.037 | 2.886 | 2.632 | 2.253 | 0.757 | 30.906 | 25.994 | 23.003 | 20.445 | 18.939 | 14.142 | 12.967 | 12.824 | 11.008 | 10.759 | 10.434 |
| Gross Profit
| 44.056 | 18.453 | 13.284 | 4.139 | 8.001 | 12.697 | 11.402 | 15.083 | 27.343 | 9.505 | 3.746 | 7.905 | 8.8 | 7.368 | 6.639 | -20.654 | -18.903 | -17.992 | -13.756 | -14.854 | -9.96 | -10.103 | -10.962 | -0.428 | -1.32 | -1.2 |
| Gross Profit Ratio
| 1 | 1 | 1 | 0.329 | 0.662 | 0.766 | 0.752 | 0.817 | 0.891 | 0.749 | 0.552 | 0.733 | 0.77 | 0.766 | 0.898 | -2.015 | -2.666 | -3.591 | -2.057 | -3.636 | -2.382 | -3.528 | -5.887 | -0.04 | -0.14 | -0.13 |
| Reseach & Development Expenses
| 78.096 | 69.663 | 67.224 | 55.481 | 46.592 | 47.96 | 47.779 | 47.856 | 45.763 | 45.816 | 46.106 | 47.761 | 47.493 | 43.137 | 36.531 | 30.906 | 25.994 | 23.003 | 20.445 | 18.939 | 14.142 | 12.967 | 12.824 | 11.008 | 10.759 | 10.434 |
| General & Administrative Expenses
| 14.282 | 11.654 | 10.717 | 11.718 | 11.71 | 11.799 | 10.78 | 10.623 | 11.678 | 9.821 | 9.367 | 9.748 | 9.654 | 9.228 | 8.818 | 8.343 | 7.511 | 6.53 | 6.252 | 4.338 | 3.27 | 2.45 | 2.602 | 2.184 | 1.87 | 1.67 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | -1.761 | -1.843 | -1.823 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 14.282 | 11.654 | 10.717 | 11.718 | 9.949 | 9.956 | 8.957 | 10.623 | 11.678 | 9.821 | 9.367 | 9.748 | 9.654 | 9.228 | 8.818 | 8.343 | 7.511 | 6.53 | 6.252 | 4.338 | 3.27 | 2.45 | 2.602 | 2.184 | 1.87 | 1.67 |
| Other Expenses
| -5.097 | -4.128 | 0 | -8.449 | 0 | 0 | 0 | -3.384 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 87.281 | 77.189 | 77.941 | 58.75 | 56.541 | 57.916 | 56.736 | 55.095 | 57.441 | 55.637 | 55.473 | 57.509 | 57.147 | 52.365 | 45.349 | 39.249 | 33.505 | 29.533 | 26.697 | 23.277 | 17.412 | 15.417 | 15.426 | 13.192 | 1.87 | 1.67 |
| Operating Income
| -48.322 | -62.864 | -64.657 | -54.611 | -48.54 | -45.219 | -45.334 | -40.012 | -26.765 | -42.952 | -48.69 | -46.718 | -45.715 | -42.322 | -37.953 | -28.997 | -26.414 | -24.522 | -20.008 | -19.192 | -13.23 | -12.553 | -13.564 | -2.612 | -3.19 | -2.87 |
| Operating Income Ratio
| -1.097 | -3.407 | -4.867 | -4.338 | -4.014 | -2.726 | -2.991 | -2.167 | -0.873 | -3.386 | -7.178 | -4.329 | -3.999 | -4.399 | -5.132 | -2.828 | -3.725 | -4.894 | -2.991 | -4.698 | -3.164 | -4.383 | -7.285 | -0.247 | -0.338 | -0.311 |
| Total Other Income Expenses Net
| 5.618 | 6.513 | 6.116 | 5.737 | 4.084 | 3.791 | 3.378 | 3.03 | 2.488 | 2.219 | 1.973 | 1.009 | 0.314 | 0.211 | 0.295 | 0.039 | 0.171 | 0.318 | 0.135 | 0.675 | 0.223 | 0.173 | 0.255 | 0.195 | 0.132 | 0.194 |
| Income Before Tax
| -42.704 | -56.351 | -58.541 | -48.874 | -44.456 | -41.428 | -41.956 | -36.982 | -24.277 | -40.733 | -46.717 | -45.709 | -45.401 | -42.533 | -37.658 | -28.958 | -26.243 | -24.204 | -19.873 | -18.517 | -13.007 | -12.38 | -13.309 | -2.417 | -3.058 | -2.676 |
| Income Before Tax Ratio
| -0.969 | -3.054 | -4.407 | -3.883 | -3.676 | -2.498 | -2.768 | -2.003 | -0.791 | -3.211 | -6.887 | -4.236 | -3.971 | -4.421 | -5.092 | -2.825 | -3.701 | -4.83 | -2.971 | -4.533 | -3.11 | -4.323 | -7.148 | -0.228 | -0.324 | -0.29 |
| Income Tax Expense
| 0.76 | 0 | 0.008 | 0.082 | 0.09 | 0.09 | 0 | 0 | -2.488 | -5.399 | -5.01 | -1.009 | -0.314 | -0.211 | 0.044 | -0.123 | 0.139 | 0.071 | 0.041 | 0 | -20.587 | 0.011 | 0.21 | 0.01 | 0.01 | 0.009 |
| Net Income
| -43.464 | -56.351 | -58.549 | -48.956 | -44.546 | -41.518 | -41.956 | -36.982 | -21.789 | -35.334 | -41.707 | -44.7 | -45.087 | -42.322 | -37.702 | -28.835 | -26.382 | -24.275 | -19.914 | -18.517 | 7.58 | -12.391 | -13.519 | -2.427 | -3.068 | -2.685 |
| Net Income Ratio
| -0.987 | -3.054 | -4.407 | -3.889 | -3.684 | -2.503 | -2.768 | -2.003 | -0.71 | -2.785 | -6.149 | -4.142 | -3.944 | -4.399 | -5.098 | -2.813 | -3.72 | -4.844 | -2.977 | -4.533 | 1.813 | -4.326 | -7.26 | -0.229 | -0.325 | -0.291 |
| EPS
| -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.4 | -0.65 | -0.77 | -0.88 | -1 | -0.95 | -0.85 | -0.65 | -0.6 | -0.63 | -0.51 | -1.09 | 0.22 | -0.6 | -0.65 | -0.12 | -0.94 | -0.85 |
| EPS Diluted
| -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.4 | -0.65 | -0.77 | -0.88 | -1 | -0.95 | -0.85 | -0.65 | -0.6 | -0.63 | -0.51 | -1.09 | 0.22 | -0.6 | -0.65 | -0.12 | -0.94 | -0.85 |
| EBITDA
| -48.322 | -58.736 | -60.354 | -50.465 | -44.449 | -41.331 | -41.577 | -36.628 | -23.432 | -39.772 | -45.653 | -42.823 | -42.769 | -40.491 | -37.196 | -28.252 | -25.643 | -23.879 | -19.364 | -18.642 | -12.735 | -12.062 | -13.015 | -2.056 | -2.587 | -2.224 |
| EBITDA Ratio
| -1.097 | -3.183 | -4.543 | -4.009 | -3.676 | -2.492 | -2.743 | -1.983 | -0.764 | -3.135 | -6.731 | -3.968 | -3.741 | -4.209 | -5.029 | -2.756 | -3.616 | -4.765 | -2.895 | -4.564 | -3.045 | -4.212 | -6.99 | -0.194 | -0.274 | -0.241 |